13 results
8-K/A
EX-10.1
CHRS
Coherus Biosciences Inc
21 May 24
Financial Statements and Exhibits
5:14pm
or limitations imposed by any Loan Document;
(n)customary provisions set forth in joint venture agreements or agreements governing minority investments … to the joint venture entity or minority investment that is the subject of such agreement;
(o)limitations imposed with respect to any license
425
SURF
Surface Oncology, Inc.
16 Jun 23
Business combination disclosure
5:11pm
and the field’s focus for immunotherapy development. While PD-1 inhibitors have revolutionized cancer therapy, still only a minority of patients respond
425
SURF
Surface Oncology, Inc.
16 Jun 23
Business combination disclosure
8:08am
but are effective in only a minority of patients. Additional overall survival gains must come from novel combinations that more broadly target the cancer
425
SURF
Surface Oncology, Inc.
16 Jun 23
Business combination disclosure
7:09am
. Existing marketed PD-1’s transformed the treatment of cancer
over the past decade but are effective in only a minority of patients. Additional
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
it as a next-generation PD-1. Existing marketed PD-1’s transformed the treatment of cancer
over the past decade but are effective in only a minority
8-K
EX-10.1
ur5b69frjkf tpr
7 Jan 22
Coherus BioSciences Secures Credit Financing
8:36am
8-K
EX-10.1
th0 hxww5tk8dqj3q3b
11 Jan 19
Entry into a Material Definitive Agreement
4:08pm
10-K
5krphsl vz50y9m41
23 Mar 15
Annual report
12:00am
424B4
xkt9ij
6 Nov 14
Prospectus supplement with pricing info
12:00am
S-1/A
jxae43o4bsz
6 Oct 14
IPO registration (amended)
12:00am
DRS/A
wo9rh7x3ix8 xtc8
15 Sep 14
Draft registration statement (amended)
12:00am
DRS
8k8u1l56k
4 Aug 14
Draft registration statement
12:00am
- Prev
- 1
- Next